Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Céline Vicente"'
Autor:
Jean-Jacques Tudesq, Mathilde Yakoub-Agha, Jacques-Olivier Bay, Corinne Courbon, Franciane Paul, Muriel Picard, Cécile Pochon, Arthur Sterin, Céline Vicente, Emmanuel Canet, Ibrahim Yakoub-Agha, Anne-Sophie Moreau
Publikováno v:
Bulletin du Cancer. 110:S116-S122
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a28592e24686dd5581f5d439ecb6476
https://doi.org/10.1016/j.bulcan.2021.11.002
https://doi.org/10.1016/j.bulcan.2021.11.002
Autor:
Muriel Picard, Arthur Sterin, Jacques-Olivier Bay, Corinne Courbon, Anne- Sophie Moreau, Franciane Paul, Cécile Pochon, Jean-Jacques Tudesq, Céline Vicente, Mathilde Yakoub-Agha, Ibrahim Yakoub-Agha
Publikováno v:
Bulletin du Cancer. 110:S123-S131
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65cb4457987f3dcf2c322ff47c0d7a62
https://doi.org/10.1016/j.bulcan.2021.12.013
https://doi.org/10.1016/j.bulcan.2021.12.013
Autor:
Ibrahim Yakoub-Agha, Cécile Pochon, Céline Vicente, Mathilde Yakoub-Agha, Anne-Sophie Moreau, Arthur Sterin, Corinne Courbon, Muriel Picard, Jean-Jacques Tudesq, Jacques-Olivier Bay, Franciane Paul
Publikováno v:
Bulletin du Cancer. 108:S98-S103
CAR-T cells are an innovative treatment for an increasing number of patients, particularly since the extension of their indication to mantle lymphoma and multiple myeloma. Several complications of CAR T-cell therapy, that were first described as exce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd59f11ee7972af222fe5106f6afd597
https://doi.org/10.1016/j.bulcan.2021.10.004
https://doi.org/10.1016/j.bulcan.2021.10.004
Autor:
Franciane Paul, Céline Vicente, Corinne Courbon, Anne-Sophie Moreau, Muriel Picard, Cécile Pochon, Arthur Sterin, Jean-Jacques Tudesq, Mathilde Yakoub-Agha, Jacques-Olivier Bay, Ibrahim Yakoub-Agha
Publikováno v:
Bulletin du Cancer. 108:S90-S97
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1529b583c32f8986122cbf17050a2918
https://doi.org/10.1016/j.bulcan.2021.11.001
https://doi.org/10.1016/j.bulcan.2021.11.001
Autor:
Tamim Alsuliman, Jean-Baptiste Mear, Aurélie Trevet, Ibrahim Yakoub-Agha, Pascale Schneider, Laurianne Drieu La Rochelle, Arnaud Campidelli, Amandine Fayard, Remy Dulery, Anne-Claire Mamez, Céline Vicente
Publikováno v:
Bulletin du Cancer. 108:S65-S71
Chimeric antigen receptor (CAR) T cells are a new class of anti-cancer therapy that involves manipulating autologous or allogeneic T cells to express a CAR directed against a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) has marketing au
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6da1451b2fda51c49478b97f5b23aa4f
https://doi.org/10.1016/j.bulcan.2020.11.015
https://doi.org/10.1016/j.bulcan.2020.11.015
Autor:
Cécile, Pochon, Corinne, Courbon, Jacques-Olivier, Bay, Anne-Sophie, Moreau, Franciane, Paul, Muriel, Picard, Arthur, Sterin, Jean-Jacques, Tudesq, Céline, Vicente, Mathilde, Yakoub-Agha, Ibrahim, Yakoub-Agha
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, 2021, 108 (12), pp.S98-S103. ⟨10.1016/j.bulcan.2021.10.004⟩
Bulletin du Cancer, 2021, 108 (12), pp.S98-S103. ⟨10.1016/j.bulcan.2021.10.004⟩
International audience; Texte de l'atelier Rappel du titre de l'atelier : Complications des cellules CAR T autres que les infections, CRS et ICANS: recommandations de la Société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5608178b75ee3f3d91f61e321f70e524
https://hal.univ-lorraine.fr/hal-03613720
https://hal.univ-lorraine.fr/hal-03613720
Autor:
Muriel, Picard, Arthur, Sterin, Jacques-Olivier, Bay, Corinne, Courbon, Anne-Sophie, Moreau, Franciane, Paul, Cécile, Pochon, Jean-Jacques, Tudesq, Céline, Vicente, Mathilde, Yakoub-Agha, Ibrahim, Yakoub-Agha
Publikováno v:
Bulletin du cancer.
The immune effector cell-associated syndrome (ICANS) has been described as the second most frequent specific complication following CAR-T cell therapy. The median time to the onset of neurological symptoms is five days after CAR-T infusion. ICANS can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::591073ccab834eb02f76037a02187c4f
https://pubmed.ncbi.nlm.nih.gov/35094839
https://pubmed.ncbi.nlm.nih.gov/35094839
Autor:
Franciane, Paul, Céline, Vicente, Corinne, Courbon, Anne-Sophie, Moreau, Muriel, Picard, Cécile, Pochon, Arthur, Sterin, Jean-Jacques, Tudesq, Mathilde, Yakoub-Agha, Jacques-Olivier, Bay, Ibrahim, Yakoub-Agha
Publikováno v:
Bulletin du cancer. 108(12S)
Infections occurring after CAR T-cells are a common complication. At the acute phase of treatment following CAR T-cell infusion, the exact incidence of infections is unknown given the overlapping symptoms with cytokine release syndrome. The risk fact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::24be92ad7cfc6e8e8d608ce2d9fd3360
https://pubmed.ncbi.nlm.nih.gov/34876272
https://pubmed.ncbi.nlm.nih.gov/34876272
Autor:
Tamim, Alsuliman, Laurianne, Drieu La Rochelle, Arnaud, Campidelli, Rémy, Duléry, Amandine, Fayard, Anne-Claire, Mamez, Jean-Baptiste, Mear, Pascale Odinet, Schneider, Aurélie, Trevet, Céline, Vicente, Ibrahim, Yakoub-Agha
Publikováno v:
Bulletin du cancer. 108(12S)
Chimeric antigen receptor (CAR) T cells are a new class of anti-cancer therapy that involves manipulating autologous or allogeneic T cells to express a CAR directed against a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) has marketing au
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5e84047f0aa5a987c41611eafba6eb15
https://pubmed.ncbi.nlm.nih.gov/33678408
https://pubmed.ncbi.nlm.nih.gov/33678408